Germany launches third DMP (disease management programme) for heart disease:
This article was originally published in Clinica
Last week the German federal insurance department (BVA) completed its guidelines for the establishment of a disease management programme (DMP) for coronary heart disease. To have a DMP accredited by the (BVA), health insurance funds must devise a programme to reduce morbidity, whilst raising the level of the patient's quality of life. The programme must also carry out diagnosis, such as coronary angiography, and offer interventional therapy, such as coronary revascularisation, in accordance with evidence-based guidelines. This is the third DMP in place since the introduction of programmes for the treatment of diabetes mellitus type II and breast cancer.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.